

JUL 07 2004

PTO/SB/97 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Certificate of Transmission under 37 CFR 1.8

OFFICIAL

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office

on July 7, 2004.

Date



Signature

Taryn Antalek

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this
certificate must identify each submitted paper.

In re: Jen et al.

USSN: 09/464,478

Filed: March 4, 2002

For: METHODS FOR THE DIAGNOSIS AND TREATMENT OF LUNG
CANCER

Examiner: Stephen L. Rawlings

Art Unit: 1642

Transmitted herewith:

Transmittal (1 sheet); Fee Transmittal (in duplicate); Response to Restriction
Requirement (5 sheets); Petition for Extension of Time (in duplicate)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/21 (02-04)


Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/646,478
	Filing Date	March 4, 2002
	First Named Inventor	Jen et al.
	Art Unit	1642
	Examiner Name	Stephen L. Rawlings
Total Number of Pages in This Submission	Attorney Docket Number	GA0130C


ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jennifer D. Tousignant GENZYME CORPORATION
Signature	
Date	7/7/04

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	TARYN ANTALAK
Signature	
Date	July 7, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Patent
Our Docket: GA0130C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1642
Jin Jen et al.)	
Serial No.: 09/646,478)	Examiner: Stephen L. Rawlings
Filed: March 4, 2002)	
For: METHODS FOR THE DIAGNOSIS)	
<u>AND TREATMENT OF LUNG CANCER</u>)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA22313-1450

**I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FACSIMILE TRANSMITTED TO THE
UNITED STATES PATENT AND TRADEMARK OFFICE FACSIMILE NUMBER (703) 872-9306 ON
July 7, 2004**

July 7, 2004
Date

TARYN ANTALEK
Printed Name of Person Signing Certificate

Request for Reconsideration of Restriction Requirement under 37 C.F.R. §1.143

This communication is being filed in response to a Restriction Requirement mailed April 7, 2004 in connection with the above-identified application. A Response to the Restriction Requirement was originally due on May 7, 2004. As part of this communication, Applicant is filing a Petition for a Two Month Extension of Time, thereby extending the deadline to file a response to July 7, 2004. Accordingly, this Response is timely filed.

In re: Jen et al.
USSN: 09/646,478
Filed: March 4, 2002
Page 2

Remarks:

Claims 1-30 are pending in the subject application and are subject to a restriction requirement.

Requirement for Restriction under 35 U.S.C. 121 and 372

In the April 7, 2004 Office Action, the Office required restriction under 35 U.S.C. § 121 and 372 to elect a single invention to which the claims must be restricted:

Group I, claim(s) 1, 2, 6, 7, 11, and 30, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed b-myb in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene, and a kit for practicing said method.

Group II, claim(s) 1, 3, 6, 8, 11, and 30, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed PGP9.5 in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene, and a kit for practicing said method.

Group III, claim(s) 1, 4, 6, 9, 11, and 30, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed 8-oxo-dGTPase in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene, and a kit for practicing said method.

Group IV, claim(s) 1, 5, 6, 10, 11, and 30, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence

of overexpressed p67 in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene, and a kit for practicing said method.

Group V, claim(s) 1, 2, 12, and 13, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed b-myb in a lung cell

In re: Jen et al.

USPN: 09/646,478

Filed: March 4, 2002

Page 3

sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

Group VI, claim(s) 1, 3, 12, and 13, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed PGP9.5 in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

Group VII, claim(s) 1, 4, 12, and 13, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed 8-oxo-dGTPase in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

Group VIII, claim(s) 1, 5, 12, and 13, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed p67 in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

Group IX, claim(s) 14 and 15, drawn to a screen for a potential therapeutic agent for the reversal of a neoplastic condition of the lung characterized by the overexpression of b-myb.

Group X, claim(s) 14 and 16, drawn to a screen for a potential therapeutic agent for the reversal of a neoplastic condition of the lung characterized by the overexpression of PGP9.5.

Group XI, claim(s) 14 and 17, drawn to a screen for a potential therapeutic agent for the reversal of a neoplastic condition of the lung characterized by the overexpression of 8-oxo-dGTPase.

Group XII, claim(s) 14 and 18, drawn to a screen for a potential therapeutic agent for the reversal of a neoplastic condition of the lung characterized by the overexpression of -67.

Group XIII, claim(s) 19, 20, and 24, drawn to a method for reversing a neoplastic condition of the lung characterized by the overexpression of b-myb.

Group XIV, claim(s) 19, 21, and 24, drawn to a method for reversing a neoplastic condition of the lung characterized by the overexpression of PGP9.5.

In re: Jen et al.
USSN: 09/646,478
Filed: March 4, 2002
Page 4

Group XV, claim(s) 19, 22, and 24, drawn to a method for reversing a neoplastic condition of the lung characterized by the overexpression of 8-oxo-dGTPase.

Group XVI, claim(s) 19, 23, and 24, drawn to a method for reversing a neoplastic condition of the lung characterized by the overexpression of -67.

Group XVII, claim(s) 25 and 29, drawn to a probe or a primer, or a solid support comprising said probe or primer, wherein said probe or primer comprises SEQ ID NO: 1 or its complement.

Group XVIII, claim(s) 26 and 29, drawn to a probe or a primer, or a solid support comprising said probe or primer, wherein said probe or primer comprises SEQ ID NO: 2 or its complement.

Group XIX, claim(s) 27 and 29, drawn to a probe or a primer, or a solid support comprising said probe or primer, wherein said probe or primer comprises SEQ ID NO: 3 or its complement.

Group XX, claim(s) 28 and 29, drawn to a probe or a primer, or a solid support comprising said probe or primer, wherein said probe or primer comprises SEQ ID NO: 4 or its complement.

Provisional election with traverse in accordance with 37 C.F.R. § 1.143

In compliance with 37 C.F.R. § 1.143, Applicants elect with traverse Group VI, claim(s) 1, 3, 12, and 13, drawn to a method for aiding in the diagnosis of a neoplastic condition of the lung comprising detecting the presence of overexpressed PGP9.5 in a lung cell sample, wherein the presence of an overexpressed proto-oncogene is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

Request for reconsideration of restriction requirement under 37 C.F.R. § 1.143

Applicants respectfully request a reconsideration and modification of this restriction requirement to the extent that it requires restriction to a single proto-oncogene from the Markush groups in claims 1, 14, and 30. The Office has failed to properly apply restriction practice under PCT Rules 13.1 and 13.2 with respect to the Markush groups present in claims 1, 14, and 30.

In re: Jen et al.
USPN: 09/646,478
Filed: March 4, 2002
Page 5.

PCT Rules 13.1 and 13.2 require a single general inventive concept to find unity of invention of claims. According to PCT Rule 13.2, this requirement can be satisfied where there is a technical relationship involving one or more special technical features. As this relates to Markush-type claims, this requirement is met when the alternatives present in the Markush-type claim are of a similar nature. (MPEP §1850 D)

Claims 1, 14, and 30 contain Markush groups that define alternative genes useful in the practice of the claimed inventions. Applicants have discovered that these genes are proto-oncogenes. These genes are thus similar in nature because 1) they are over-expressed in lung cancer cells and 2) their overexpression is indicative of the neoplastic state of a lung cell. Applicants assert that the similar nature of these Markush group members satisfies PCT Rule 13.2 and that the restriction to a single proto-oncogene is improper.

Since the unity of invention required under PCT 13.2 is satisfied, Applicants respectfully request modification of the restriction requirement to reflect the Office's national restriction practice with respect to Markush-type claims that are directed to independent and distinct inventions in U.S. national applications filed under 35 U.S.C. § 111 outside the PCT. Applicants respectfully suggest that the restriction requirement be modified to require a provisional election of a single, patentably distinct species of proto-oncogene in the claimed methods with respect to which the Markush claim will be fully examined to determine patentability and where the search of the Markush group will be extended to additional members should no prior art be found that anticipates or renders obvious the elected proto-oncogene.

If this requirement is not modified and is made final by the Examiner, Applicants further reserve the right to petition from requirement for restriction under 37 C.F.R. §1.144.


Conclusion:

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

7/7/04

Date



Jennifer D. Tousignant
Agent for Applicants
Registration No. 54,498
Telephone: (508) 270-2499
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322